Evidence map›Paper›PMID 28413676›Full record

ArticleMolecular and clinical oncology2017

Expression patterns of CD168 correlate with the stage and grade of squamous cell carcinoma of head and neck.

Korinna Jöhrens, Ioannis Anagnostopoulos, Steffen Dommerich, Jan Dirk Raguse, Agnieszka J Szczepek, Frederick Klauschen, Katharina Stölzel

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Korinna JöhrensInstitute of Pathology, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Ioannis AnagnostopoulosInstitute of Pathology, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Steffen DommerichDepartment of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Jan Dirk RaguseDepartment of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin, Campus Charité Virchow-Klinikum, D-13353 Berlin, Germany.
Agnieszka J SzczepekDepartment of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Frederick KlauschenInstitute of Pathology, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Katharina StölzelDepartment of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin, Campus Charité Mitte, D-10117 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptor for hyaluronan-mediated motility CD168 is associated with the processes of oncogenesis and metastasis. The objective of the present study was to determine the possible association between the expression and distribution of CD168 and the tumor stage of head-and-neck squamous cell carcinoma (SCC). Formalin-fixed and paraffin-embedded tumor samples obtained from 100 patients during primary resection of SCC from the oral cavity, oropharynx, hypopharynx or larynx were included in the present study. The patients were divided into two risk groups: Low risk, representing the early stage of completely resected SCCs with good-to-moderate differentiation, and the high-risk group, representing the advanced stage SCCs with positive resection margins, vascular invasion or locoregional metastasis. All specimens were stained with a monoclonal antibody against CD168. Percentage and staining intensity of CD168-positive cells were scored, and their spatial distribution within the tumor nests was noted. The results obtained were correlated with the tumor stage. The quantification of CD168 expression revealed significant differences between the two risk groups (t-test, P=0.002), with higher scores in tumors resected from the high-risk SSC group compared with those from the low-risk group. In addition, in the high-risk group, the CD168-positive cells were present predominantly in the periphery (70.4%) of tumor nests, whereas in the low-risk group, only 56.6% were located there; however, this trend did not reach the level of statistical significance. Taken together, the results from the present study suggested that CD168 expression patterns could potentially be used as a predictor of tumor aggressiveness, and therefore they may be a prognostic factor in head-and-neck SCC.

Indexed as

CD168high-risk tumorslow-risk tumorssquamous cell carcinoma of head and neck

Identifiers

PMID28413676
PMCPMC5374904
OpenAlexW2588117259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.